Somatostatin Analogues according to Ki67 index in neuroendocrine tumours

An observational retrospective-prospective analysis from real life

Antongiulio Faggiano, Anna Chiara Carratù, Elia Guadagno, Salvatore Tafuto, Fabiana Tatangelo, Ferdinando Riccardi, Carmela Mocerino, Giovannella Palmieri, Vincenzo Damiano, Roberta Siciliano, Silvana Leo, Annamaria Mauro, Lucia Franca Tozzi, Gaetano De Rosa, Annamaria Colao

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Somatostatin analogues (SSAs) have shown limited and variable antiproliferative effects in neuroendocrine tumours (NETs). Whether tumour control by SSAs depends on grading based on the 2010 WHO NET classification is still unclear. The aim of this study is to evaluate the efficacy of long-acting SSAs in NETs according to Ki67 index. An observational Italian multicentre study was designed to collect data in patients with gastro-entero-pancreatic or thoracic NETs under SSA treatment. Both retrospective and prospective data were included and they were analysed in line with Ki67 index, immunohistochemically evaluated in tumour samples and graded according to WHO classification (G1 = Ki67 index 0-2%, G2 = Ki67 index 3-20%, G3 = Ki67 index > 20%). Among 601 patients with NET, 140 with a histologically confirmed gastro-entero-pancreatic or thoracic NET or NET with unknown primary were treated with lanreotide autogel or octreotide LAR. An objective tumour response was observed in 11%, stability in 58% and progression in 31%. Objective response and tumour stability were not significantly different between G1 and G2 NETs. Progression free survival was longer but not significantly different in G1 than G2 NETs (median: 89 vs 43 months, p = 0.15). The median PFS was significantly longer in NETs showing Ki67 <5% than in those showing Ki67 ≥5% (89 vs 35 months, p = 0.005). SSA therapy shows significant antiproliferative effects in well differentiated low/intermediate-proliferating NETs, not only G1 but also in G2 type. A Ki67 index of 5% seems to work better than 3% to select the best candidates for SSA therapy.

Original languageEnglish
Pages (from-to)5538-5547
Number of pages10
JournalOncotarget
Volume7
Issue number5
DOIs
Publication statusPublished - 2016

Fingerprint

Neuroendocrine Tumors
Somatostatin
Neoplasms
Thorax
Octreotide
Multicenter Studies
Disease-Free Survival
Therapeutics

Keywords

  • Ki67 index
  • Lanreotide
  • Neuroendocrine tumours
  • Octreotide
  • Somatostatin analogues

ASJC Scopus subject areas

  • Oncology

Cite this

Somatostatin Analogues according to Ki67 index in neuroendocrine tumours : An observational retrospective-prospective analysis from real life. / Faggiano, Antongiulio; Carratù, Anna Chiara; Guadagno, Elia; Tafuto, Salvatore; Tatangelo, Fabiana; Riccardi, Ferdinando; Mocerino, Carmela; Palmieri, Giovannella; Damiano, Vincenzo; Siciliano, Roberta; Leo, Silvana; Mauro, Annamaria; Tozzi, Lucia Franca; De Rosa, Gaetano; Colao, Annamaria.

In: Oncotarget, Vol. 7, No. 5, 2016, p. 5538-5547.

Research output: Contribution to journalArticle

Faggiano, A, Carratù, AC, Guadagno, E, Tafuto, S, Tatangelo, F, Riccardi, F, Mocerino, C, Palmieri, G, Damiano, V, Siciliano, R, Leo, S, Mauro, A, Tozzi, LF, De Rosa, G & Colao, A 2016, 'Somatostatin Analogues according to Ki67 index in neuroendocrine tumours: An observational retrospective-prospective analysis from real life', Oncotarget, vol. 7, no. 5, pp. 5538-5547. https://doi.org/10.18632/oncotarget.6686
Faggiano, Antongiulio ; Carratù, Anna Chiara ; Guadagno, Elia ; Tafuto, Salvatore ; Tatangelo, Fabiana ; Riccardi, Ferdinando ; Mocerino, Carmela ; Palmieri, Giovannella ; Damiano, Vincenzo ; Siciliano, Roberta ; Leo, Silvana ; Mauro, Annamaria ; Tozzi, Lucia Franca ; De Rosa, Gaetano ; Colao, Annamaria. / Somatostatin Analogues according to Ki67 index in neuroendocrine tumours : An observational retrospective-prospective analysis from real life. In: Oncotarget. 2016 ; Vol. 7, No. 5. pp. 5538-5547.
@article{c2ddbd137a6b4b97ac1a9c13bdea9a11,
title = "Somatostatin Analogues according to Ki67 index in neuroendocrine tumours: An observational retrospective-prospective analysis from real life",
abstract = "Somatostatin analogues (SSAs) have shown limited and variable antiproliferative effects in neuroendocrine tumours (NETs). Whether tumour control by SSAs depends on grading based on the 2010 WHO NET classification is still unclear. The aim of this study is to evaluate the efficacy of long-acting SSAs in NETs according to Ki67 index. An observational Italian multicentre study was designed to collect data in patients with gastro-entero-pancreatic or thoracic NETs under SSA treatment. Both retrospective and prospective data were included and they were analysed in line with Ki67 index, immunohistochemically evaluated in tumour samples and graded according to WHO classification (G1 = Ki67 index 0-2{\%}, G2 = Ki67 index 3-20{\%}, G3 = Ki67 index > 20{\%}). Among 601 patients with NET, 140 with a histologically confirmed gastro-entero-pancreatic or thoracic NET or NET with unknown primary were treated with lanreotide autogel or octreotide LAR. An objective tumour response was observed in 11{\%}, stability in 58{\%} and progression in 31{\%}. Objective response and tumour stability were not significantly different between G1 and G2 NETs. Progression free survival was longer but not significantly different in G1 than G2 NETs (median: 89 vs 43 months, p = 0.15). The median PFS was significantly longer in NETs showing Ki67 <5{\%} than in those showing Ki67 ≥5{\%} (89 vs 35 months, p = 0.005). SSA therapy shows significant antiproliferative effects in well differentiated low/intermediate-proliferating NETs, not only G1 but also in G2 type. A Ki67 index of 5{\%} seems to work better than 3{\%} to select the best candidates for SSA therapy.",
keywords = "Ki67 index, Lanreotide, Neuroendocrine tumours, Octreotide, Somatostatin analogues",
author = "Antongiulio Faggiano and Carrat{\`u}, {Anna Chiara} and Elia Guadagno and Salvatore Tafuto and Fabiana Tatangelo and Ferdinando Riccardi and Carmela Mocerino and Giovannella Palmieri and Vincenzo Damiano and Roberta Siciliano and Silvana Leo and Annamaria Mauro and Tozzi, {Lucia Franca} and {De Rosa}, Gaetano and Annamaria Colao",
year = "2016",
doi = "10.18632/oncotarget.6686",
language = "English",
volume = "7",
pages = "5538--5547",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "5",

}

TY - JOUR

T1 - Somatostatin Analogues according to Ki67 index in neuroendocrine tumours

T2 - An observational retrospective-prospective analysis from real life

AU - Faggiano, Antongiulio

AU - Carratù, Anna Chiara

AU - Guadagno, Elia

AU - Tafuto, Salvatore

AU - Tatangelo, Fabiana

AU - Riccardi, Ferdinando

AU - Mocerino, Carmela

AU - Palmieri, Giovannella

AU - Damiano, Vincenzo

AU - Siciliano, Roberta

AU - Leo, Silvana

AU - Mauro, Annamaria

AU - Tozzi, Lucia Franca

AU - De Rosa, Gaetano

AU - Colao, Annamaria

PY - 2016

Y1 - 2016

N2 - Somatostatin analogues (SSAs) have shown limited and variable antiproliferative effects in neuroendocrine tumours (NETs). Whether tumour control by SSAs depends on grading based on the 2010 WHO NET classification is still unclear. The aim of this study is to evaluate the efficacy of long-acting SSAs in NETs according to Ki67 index. An observational Italian multicentre study was designed to collect data in patients with gastro-entero-pancreatic or thoracic NETs under SSA treatment. Both retrospective and prospective data were included and they were analysed in line with Ki67 index, immunohistochemically evaluated in tumour samples and graded according to WHO classification (G1 = Ki67 index 0-2%, G2 = Ki67 index 3-20%, G3 = Ki67 index > 20%). Among 601 patients with NET, 140 with a histologically confirmed gastro-entero-pancreatic or thoracic NET or NET with unknown primary were treated with lanreotide autogel or octreotide LAR. An objective tumour response was observed in 11%, stability in 58% and progression in 31%. Objective response and tumour stability were not significantly different between G1 and G2 NETs. Progression free survival was longer but not significantly different in G1 than G2 NETs (median: 89 vs 43 months, p = 0.15). The median PFS was significantly longer in NETs showing Ki67 <5% than in those showing Ki67 ≥5% (89 vs 35 months, p = 0.005). SSA therapy shows significant antiproliferative effects in well differentiated low/intermediate-proliferating NETs, not only G1 but also in G2 type. A Ki67 index of 5% seems to work better than 3% to select the best candidates for SSA therapy.

AB - Somatostatin analogues (SSAs) have shown limited and variable antiproliferative effects in neuroendocrine tumours (NETs). Whether tumour control by SSAs depends on grading based on the 2010 WHO NET classification is still unclear. The aim of this study is to evaluate the efficacy of long-acting SSAs in NETs according to Ki67 index. An observational Italian multicentre study was designed to collect data in patients with gastro-entero-pancreatic or thoracic NETs under SSA treatment. Both retrospective and prospective data were included and they were analysed in line with Ki67 index, immunohistochemically evaluated in tumour samples and graded according to WHO classification (G1 = Ki67 index 0-2%, G2 = Ki67 index 3-20%, G3 = Ki67 index > 20%). Among 601 patients with NET, 140 with a histologically confirmed gastro-entero-pancreatic or thoracic NET or NET with unknown primary were treated with lanreotide autogel or octreotide LAR. An objective tumour response was observed in 11%, stability in 58% and progression in 31%. Objective response and tumour stability were not significantly different between G1 and G2 NETs. Progression free survival was longer but not significantly different in G1 than G2 NETs (median: 89 vs 43 months, p = 0.15). The median PFS was significantly longer in NETs showing Ki67 <5% than in those showing Ki67 ≥5% (89 vs 35 months, p = 0.005). SSA therapy shows significant antiproliferative effects in well differentiated low/intermediate-proliferating NETs, not only G1 but also in G2 type. A Ki67 index of 5% seems to work better than 3% to select the best candidates for SSA therapy.

KW - Ki67 index

KW - Lanreotide

KW - Neuroendocrine tumours

KW - Octreotide

KW - Somatostatin analogues

UR - http://www.scopus.com/inward/record.url?scp=84958068656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958068656&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.6686

DO - 10.18632/oncotarget.6686

M3 - Article

VL - 7

SP - 5538

EP - 5547

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 5

ER -